One of the nation’s leading cancer centers will no longer offer Zantac and its generics to patients, as it reviews the potential cancer risk from the discovery of a carcinogen in the popular stomach pills.
Memorial Sloan Kettering Cancer Center is removing Zantac products from the list of drugs that it offers patients “out of caution due to a recent product alert from the Food and Drug Administration,” Caitlin Hool, a spokeswoman for the New York-based center, said in an email on Monday. The process will take a few weeks, she said.
